

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 001-14053

**MILESTONE SCIENTIFIC INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation or organization)

**13-3545623**

(I.R.S. Employer Identification No.)

**220 South Orange Avenue, Livingston, New Jersey 07039**

(Address of principal executive offices)

**(973) 535-2717**

(Registrant's telephone number, including area code)

---

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company)

Accelerated filer

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No

As of May 13, 2014, the Issuer had a total of 17,905,465 shares of Common Stock, \$.001 par value outstanding.

MILESTONE SCIENTIFIC INC

TABLE OF CONTENTS

**PART I - FINANCIAL INFORMATION**

<b>Item 1. Financial Statements</b>	
<b>Condensed Balance Sheets</b>	
<b>March 31, 2014 (Unaudited) and December 31, 2013 (Audited)</b>	<b>4</b>
<b>Condensed Statements of Income</b>	
<b>Three Months Ended March 31, 2014 and 2013 (Unaudited)</b>	<b>5</b>
<b>Condensed Statement of Changes in Stockholders' Equity</b>	
<b>Three Months Ended March 31, 2014 (Unaudited)</b>	<b>6</b>
<b>Condensed Statements of Cash Flows</b>	
<b>Three Months Ended March 31, 2014 and 2013 (Unaudited)</b>	<b>7</b>
<b>Notes to Condensed Financial Statements (Unaudited)</b>	<b>8</b>
<b>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.</b>	<b>15</b>
<b>Item 3. Quantitative and Qualitative Disclosures About Market Risk.</b>	<b>20</b>
<b>Item 4. Controls and Procedures</b>	<b>20</b>

**PART II - OTHER INFORMATION**

<b>Item 1. Legal Proceedings.</b>	<b>21</b>
<b>Item 1A. Risk Factors.</b>	<b>21</b>
<b>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</b>	<b>21</b>
<b>Item 3. Defaults Upon Senior Securities.</b>	<b>21</b>
<b>Item 4. Mine Safety Disclosures.</b>	<b>21</b>
<b>Item 5. Other Information.</b>	<b>21</b>
<b>Item 6. Exhibits</b>	<b>21</b>

**SIGNATURES**

## **FORWARD-LOOKING STATEMENTS**

*When used in this Quarterly Report on Form 10-Q, the words “may”, “will”, “should”, “expect”, “believe”, “anticipate”, “continue”, “estimate”, “project”, “intend” and similar expressions are intended to identify forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) regarding events, conditions and financial trends that may affect Milestone’s future plans of operations, business strategy, results of operations and financial condition. Milestone wishes to ensure that such statements are accompanied by meaningful cautionary statements pursuant to the safe harbor established in the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties and the actual results may differ materially from those included within the forward-looking statements as a result of various factors. Such forward-looking statements should, therefore, be considered in light of various important factors, including those set forth herein and others set forth from time to time in Milestone’s reports and registration statements filed with the Securities and Exchange Commission (the “Commission”). Milestone disclaims any intent or obligation to update such forward-looking statements.*

MILESTONE SCIENTIFIC INC.  
CONDENSED BALANCE SHEETS

	March 31, 2014 (Unaudited)	December 31, 2013 (Audited)
<u>ASSETS</u>		
Current Assets:		
Cash and cash equivalents	\$ 1,398,847	\$ 1,147,198
Accounts receivable, net of allowance for doubtful accounts of \$5,000 as of March 31, 2014 and \$5,000 as of December 31, 2013	1,221,375	1,532,856
Inventories	1,744,946	1,321,652
Advances on contracts	1,763,280	727,478
Prepaid expenses and other current assets	242,718	150,451
Total current assets	6,371,166	4,879,635
Advances on contracts	218,875	1,580,874
Investment in Milestone Medical Inc	852,295	924,115
Investment in Milestone Education LLC	38,666	42,082
Furniture, Fixtures & Equipment net of accumulated depreciation of \$458,614 as of March 31, 2014 and \$476,884 as of December 31, 2013	24,562	23,988
Patents, net of accumulated amortization of \$518,095 as of March 31, 2014 and \$498,502 as of December 31, 2013	572,142	591,735
Other assets	12,917	12,917
Total assets	\$ 8,090,623	\$ 8,055,346
<u>LIABILITIES AND STOCKHOLDERS' EQUITY</u>		
Current Liabilities:		
Accounts payable	\$ 1,217,135	\$ 2,020,368
Customer advances	507,345	-
Accrued expenses and other payables	484,012	515,133
Total current liabilities	2,208,492	2,535,501
Commitments and Contingencies		
Stockholders' Equity		
Preferred Stock, par value \$.001, 5,000,000 shares	-	-
Common stock, par value \$.001; authorized 50,000,000 shares; 17,780,465 shares issued, 1,964,930 shares to be issued and 17,747,132 shares outstanding as of March 31, 2014; 17,759,540 shares issued, 1,839,930 shares to be issued and 17,726,207 shares outstanding as of December 31, 2013	19,745	19,599
Additional paid-in capital	66,844,506	66,677,200
Accumulated deficit	(60,070,604)	(60,265,438)
Treasury stock, at cost, 33,333 shares	(911,516)	(911,516)
Total stockholders' equity	5,882,131	5,519,846
Total liabilities and stockholders' equity	\$ 8,090,623	\$ 8,055,347

See Notes to Condensed Financial Statements

MILESTONE SCIENTIFIC INC.  
CONDENSED STATEMENTS OF INCOME  
(Unaudited)

	Three Months Ended March 31,	
	2014	2013
Net sales	\$ 2,620,834	\$ 2,489,542
Cost of products sold	882,997	812,043
Gross profit	1,737,837	1,677,499
Selling, general and administrative expenses	1,392,869	1,387,901
Research and development expenses	15,720	121,837
Total operating expenses	1,408,589	1,509,738
Income from operations	329,248	167,761
Other income (expenses)		
Other income	-	17,543
Interest expense	(475)	(34,558)
Loss from Medical Joint Venture	(130,523)	-
Loss from Education Joint Venture	(3,416)	-
Total other expenses, net	(134,414)	(17,015)
Net income	\$ 194,834	\$ 150,746
Net income		
Basic	\$ 0.01	\$ 0.01
Diluted	\$ 0.01	\$ 0.01
Weighted average shares outstanding and to be issued -		
Basic	17,787,352	16,351,894
Diluted	18,268,814	16,752,580

See Notes to Condensed Financial Statements

MILESTONE SCIENTIFIC INC.  
CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY  
THREE MONTHS ENDED MARCH 31, 2014  
(Unaudited)

	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Treasury Stock	Total
	Shares	Amount				
Balance, January 1, 2014	19,599,470	\$ 19,599	\$ 66,677,200	\$ (60,265,438)	\$ (911,516)	\$ 5,519,845
Options issued to employees and consultants	-	-	39,877	-	-	39,877
Exercise of stock options to be issued	95,000	95	37,905	-	-	38,000
Common stock to be issued for directors compensation	30,000	30	55,170	-	-	55,200
Common stock issued for payment of consulting services	13,939	14	22,486	-	-	22,500
Common stock issued for payment of employee compensation	6,986	7	11,868	-	-	11,875
Net income	-	-	-	194,834	-	194,834
Balance, March 31, 2014	19,745,395	\$ 19,745	\$ 66,844,506	\$ (60,070,604)	\$ (911,516)	\$ 5,882,131

See Notes to Condensed Financial Statements

MILESTONE SCIENTIFIC INC.  
CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)

	Three Months Ended March 31,	
	2014	2013
Cash flows from operating activities:		
Net income	\$ 194,834	\$ 150,746
Adjustments to reconcile net income to net cash provided by (used in) operating activities:		
Depreciation expense	4,041	4,400
Amortization of patents	19,593	19,375
Common stock and options for compensation, consulting and vendor services	88,052	280,610
Accrued interest expense on notes payable	-	24,419
Bad debt reversal	-	(55,987)
Loss on Earnings on Medical Joint Venture	130,523	-
Loss on Earnings on Education Venture	3,416	-
Changes in operating assets and liabilities:		
Decrease (Increase) in accounts receivable	311,481	(246,594)
(Increase) Decrease in inventories	(423,294)	13,012
Decrease to advance on contracts	326,197	39,756
(Increase) Decrease to prepaid expenses and other current assets	(50,866)	73,119
Decrease in accounts payable	(803,233)	(306,322)
Increase in customer advances	507,345	-
Decrease in accrued expenses	(31,121)	(80,201)
Net cash provided by (used in) operating activities	276,968	(83,667)
Cash flows from investing activities:		
Investment in Medical Joint Venture	(58,703)	-
Investment in Education Joint Venture	-	(50,000)
Purchases of property and equipment	(4,616)	(856)
Payment for patents rights	-	(9,122)
Net cash used in investing activities	(63,319)	(59,978)
Cash flows from financing activities:		
Proceeds from exercise of stock options	38,000	-
Proceeds from the sale of common stock	-	50,000
Proceeds from loan from related party	-	50,000
Net cash provided by financing activities	38,000	100,000
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	251,649	(43,645)
Cash and cash equivalents at beginning of period	1,147,198	165,249
Cash and cash equivalents at end of period	\$ 1,398,847	\$ 121,604
Supplemental disclosure of non cash investing and financing activities:		
Shares issued to employees in lieu of cash compensation	\$ 11,875	\$ 11,875
Shares to be issued to directors for prepaid directors' fees	\$ 55,200	\$ -

See Notes to Condensed Financial Statements

## **MILESTONE SCIENTIFIC INC.**

### **NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED) March 31, 2014**

#### **ORGANIZATION, BUSINESS AND BASIS OF PRESENTATION**

Milestone Scientific Inc. (“Milestone”) or (“our”) was incorporated in the State of Delaware in August 1989.

The unaudited financial statements of Milestone have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

These unaudited financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2013 included in Milestone's Annual Report on Form 10-K.

In the opinion of management, the accompanying unaudited financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present Milestone’s financial position as of March 31, 2014 and the results of its operations for the three months then ended.

The results reported for the three months ended March 31, 2014 are not necessarily indicative of the results of operations which may be expected for a full year.

Milestone has incurred significant operating losses since its inception. Milestone had positive cash flows from operating activities for the three months ending March 31, 2014 of \$276,968 and a negative cash flow of \$83,667 for the three months ended March 31, 2013. At March 31, 2014, Milestone had cash and cash equivalents of \$1,398,847 and a positive working capital of \$4,162,674. The working capital increased by \$1,818,540 as compared to December 31, 2013. The positive change in working capital is due to Milestone’s increased profitability and net cash flow resulting in an increase in current assets (cash, accounts receivable and classification of advances on contracts from noncurrent to current) and a reduction in accounts payable. Milestone is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue based upon management’s assessment of present contracts and current negotiations and reductions in operating expenses. As of March 31, 2014, Milestone does not have sufficient cash reserves to meet all of its anticipated obligations for the next twelve months. Milestone may require the need for a higher level of marketing and sales efforts that at present it cannot fund. If Milestone is unable to continue to generate positive cash flows from its operating activities it will need to raise additional capital. There is no assurance that Milestone will be able to continue to generate positive operating cash flows or that additional capital can be raised on terms and conditions satisfactory to Milestone, if at all. If positive cash flow cannot be continued to be achieved or if additional capital is required and it cannot be raised, then Milestone would be forced to curtail its development activities, reduce marketing expenses for existing dental products or adopt other cost saving measures, any of which might negatively affect Milestone’s operating results.

Milestone’s historical losses, and the matters discussed above, raise substantial doubt about its ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

## **NOTE -1 SUMMARY OF ACCOUNTING POLICIES**

### **Recent Accounting Pronouncements**

For a discussion of recent accounting pronouncements please refer to Note 2, "Summary of Significant Accounting Policies," in the 2013 Annual Report on Form 10-K. Milestone did not adopt any new accounting pronouncements during the three months ended March 31, 2014 that had a material effect on Milestone's condensed financial statements.

### **NOTE – 2 BASIC AND DILUTED NET INCOME (LOSS) PER COMMON SHARE**

Milestone presents "basic" and "fully diluted" earnings (loss) per common share applicable to common stockholders, and, if applicable, "diluted" earnings (loss) per common share applicable to common stockholders pursuant to the provisions of FASB ASC Topic 260. Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued during each period. The calculation of diluted earnings per common share is similar to that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and warrants were issued during the period.

For the quarters ending March 31, 2014 and 2013, Milestone calculated basic and fully diluted earnings per common share as described in the previous paragraph.

### **NOTE – 3 ACCOUNTS RECEIVABLE**

Milestone sells a significant amount of its product on credit terms to its major distributors. Milestone estimates losses from the inability of its customers to make payments on amounts billed. A majority of credit sales are due within ninety days from invoicing.

### **NOTE – 4 INVESTMENT IN JOINT VENTURES**

In March 2011, Milestone entered into an agreement with a People's Republic of China ("PRC") entity Beijing 3H Scientific Technology Co., Ltd (Beijing 3H), to establish a Medical Joint Venture entity in the PRC to develop intra-articular and epidural drug delivery instruments utilizing Milestone's patented *CompuFlo* technology (the "Medical Joint Venture"). Beijing 3H agreed to contribute up to \$1.5 million to this Medical Joint Venture entity, based on progress reports from Milestone and subject to refund if the instruments are not developed because of technological problems within 30 months of the inception date. Milestone evaluates the technological feasibility of the products to be developed using the *CompuFlo* technology periodically and at every reporting date to establish if circumstances indicate that the technology continues to be feasible. Based on the available evidence Milestone concluded that the contingency associated with the return of capital to Beijing 3H no longer existed as of December 31, 2013, since the instruments have advanced beyond the development stage and accordingly no amounts have been accrued in the accompanying financial statements relating to this contingency. Milestone, with the consent of Beijing 3H, organized a domestic research and development corporation to which the principal shareholders of Beijing 3H and other shareholders completed a capital contribution of \$ 1,500,000. The Medical Joint Venture entity was initially owned fifty percent by shareholders of Beijing 3H and fifty percent by Milestone. Milestone contributed an exclusive worldwide royalty-free license to use *CompuFlo* technology to the Medical Joint Venture which had a net book value of approximately \$245,000 and has accounted for its investment in the Medical Joint Venture using the equity method of accounting. Further, Milestone was authorized by the Medical Joint Venture to manage and oversee the development of the two products for the Medical Joint Venture. In connection with this authorization, Milestone also entered into an agreement with a significant vendor to develop the two instruments included in the Medical Joint Venture.

Milestone will have distribution responsibility in the U.S. and Canada. Beijing 3H will distribute products exclusively in the PRC, Macao, Hong Kong and other regions of Asia. The rest of the world responsibilities will be shared by Milestone and Beijing 3H.

In July 2013, Milestone entered a strategic partnership with the largest provider of specialty sales and distribution solutions for healthcare in the United States. During the three year strategic partnership, the distributor will hold the exclusive rights to market, resell, label and distribute Milestone's *CompuFlo* injection technology for use in epidural applications for childbirth and other pain management needs in hospitals in the U.S.

In the fourth quarter of 2013, Milestone Medical issued 2 million shares of its common stock in a private placement offering at \$1.50 per share (\$3.0 million) in Poland. As a result of this sale, Milestone Medical received net proceeds of \$2,363,000. The effect of this sale of new shares was to reduce Milestone's ownership percentage from 50% to 45.5% (post transaction). Consistent with the equity method of accounting, the dilution in ownership percentage is treated as if the decreased percentage of ownership was the result of the sale of these shares. As a result, Milestone recorded in the fourth quarter of 2013, a \$1,363,650 gain on dilution effect on Medical Joint Venture.

Milestone recorded a Loss on Medical Joint Venture of \$130,523. The losses described represent 45.5% of the applicable losses recorded by the Medical Joint Venture during the three months ended March 31, 2014. Milestone utilizes the equity method of accounting to recognize its financial results of the joint venture.

Milestone expended \$39,153 on behalf of the joint venture in the year ended December 31, 2013 for legal fees related to the FDA (510k) certifications. As part of the joint venture agreement, Milestone is to pay all fees related to the USA FDA certification process.

Milestone has an investment in the Joint Venture of \$852,295 at March 31, 2014 and there are no remaining suspended losses.

The Medical Joint Venture's cumulative expenses through for the quarter ending March 31, 2014 were approximately \$287,000.

On July 1, 2013, Milestone and Milestone Medical Inc., a medical joint venture 45.5 percent of which is owned by Milestone, signed an agreement for the reimbursement of specific expenses incurred by Milestone Scientific Inc. specifically for the benefit of Milestone Medical Inc. The expenses related to the agreement that have not been paid are \$48,641 as of March 31, 2014 and are included in accounts receivable, net. This includes \$24,553 of charges for the three months ended March 31, 2014.

In the first quarter of 2013, the CEO of Milestone loaned Milestone \$50,000 for use in capitalizing a fifty percent equity portion in the joint venture with Milestone Education LLC (the "Education Joint Venture"). This balance is included in the accrued expenses on the condensed balance sheets. There is no interest to this agreement and the loan was paid in April 2014.

The Education Joint Venture is expected to provide training and education to our dentists throughout the world. Milestone accounted for its investment in the Education Joint Venture using the equity method of accounting. Milestone Education LLC began operations in 2013. The investment in the Education Joint Venture is accounted for under the equity method of accounting. As of March 31, 2014, the Education Joint Venture has incurred a loss of \$6,830 and fifty percent of these losses are recorded in the Statement of Income for Milestone.

## **NOTE – 5 STOCK OPTION PLANS**

A summary of option activity for employees under the plans and changes during the three months ended March 31, 2014, is presented below:

	<b>Number of Options</b>	<b>Weighted Averaged Exercise Price \$</b>	<b>Weighted Average Remaining Contractual Life (Years)</b>	<b>Aggregate Intrinsic Options Value \$</b>
Outstanding, January 1, 2014	1,484,499	1.03	2.88	996,554
Granted	6,024	1.65	4.75	-
Exercised	60,000	0.40	-	-
Forfeited or expired	-	-	-	-
Outstanding, March 31, 2014	1,430,523	1.06	2.72	792,444
Exercisable, March 31, 2014	1,079,232	1.00	2.28	662,178

Milestone recognizes stock compensation expense on a straight line basis over the requisite service period. During the three months ended March 31, 2014, Milestone recognized \$39,877 of total stock compensation cost. As of March 31, 2014, there was \$357,790 of total unrecognized compensation cost related to non-vested options which Milestone expects to recognize over a weighted average period of 2.50 years. A six percent rate of forfeitures is assumed in the calculation of the compensation cost for the period.

Expected volatilities are based on historical volatility of Milestone's common stock over a period commensurate with the anticipated term. Milestone uses historical data to estimate option exercise and employee termination within the valuation model.

A summary of option activity for non-employees under the plans and changes during the three months ended March 31, 2014, is presented below:

	<b>Number of Options</b>	<b>Weighted Averaged Exercise Price \$</b>	<b>Weighted Average Remaining Contractual Life (Years)</b>	<b>Aggregate Intrinsic Options Value \$</b>
Outstanding, January 1, 2014	173,332	0.48	0.59	210,833
Granted	-	-	-	-
Exercised	35,000	0.40	-	-
Forfeited or expired	-	-	-	-
Outstanding, March 31, 2014	138,332	0.50	0.43	151,499
Exercisable, March 31, 2014	138,332	0.50	0.43	151,499

During the three months ended March 31, 2014, Milestone had no expenses related to non-employee options that vested during the period. There was no unrecognized compensation cost related to non-vested options as of March 31, 2014. A six percent rate of forfeitures is assumed in the calculation of the compensation cost for the period.

In accordance with the provisions of FASB ASC 505-50-15, all other issuances of common stock, stock options or other equity instruments to non-employees as consideration for goods or services received by Milestone are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of any options or similar equity instruments issued is estimated based on the Black-Scholes option-pricing model and the assumption that all of the options or other equity instruments will ultimately vest. Such fair value is measured as of an appropriate date pursuant to the guidance, (generally, the earlier of the date the other party becomes committed to provide goods or services or the date of performance by the other party is complete) and capitalized or expensed as if Milestone had paid cash for the goods or services.

## **NOTE – 6 CONCENTRATION OF CREDIT RISK**

Milestone's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and trade accounts receivable, and advances on contracts. Milestone places its cash and cash equivalents with large financial institutions. At times, such investments may be in excess of the Federal Deposit Insurance Corporation insurance limit. Milestone has not experienced any losses in such accounts and believes it is not exposed to any significant credit risks. Financial instruments which potentially subject Milestone to credit risk consist principally of trade accounts receivable, as Milestone does not require collateral or other security to support customer receivables, and advances on contracts. Milestone entered into a purchase agreement with a vendor to supply Milestone with 12,000 *STA Instruments* (5,633 instruments are remaining on the purchase order as of March 31, 2014). As part of these agreements, Milestone has advanced approximately \$1,982,000 and \$2,308,000 to the vendor for purchase of materials at March 31, 2014 and December 31, 2013, respectively. The advance will be credited to Milestone as the goods are delivered. Milestone does not believe that significant credit risk exists with respect to this advance to the contract manufacturer.

Milestone closely monitors the extension of credit to its customers while maintaining allowances, if necessary, for potential credit losses. On a periodic basis, Milestone evaluates its accounts receivable and establishes an allowance for doubtful accounts, based on a history of past write-offs and collections and current credit conditions. Management has provided a reserve that it believes is sufficient record accounts receivable at net realizable value as of March 31, 2014 and December 31, 2013.

## **NOTE – 7 ADVANCES ON CONTRACTS**

The advances on contracts represent funding of future *STA* inventory purchases. The balance of the advances as of March 31, 2014 and December 31, 2013 is \$1,982,155 and \$2,308,352, respectively. The portion of the advance that is expected to be utilized in the next twelve months is classified as current asset, with the remainder classified as non-current asset.

## **NOTE – 8 CUSTOMER ADVANCES**

As of March 31, 2014, several customers paid in advance for future shipments of merchandise. These advanced payments will be reduced as shipments are made in 2014.

## **NOTE – 9 NOTE PAYABLE**

Milestone borrowed \$450,000 from a shareholder in 2008. The loan was originally a short term loan with a maturity date of January 19, 2009. In December 2008, May 30, 2012 and March 29, 2013, this loan was extended and the due date was last fixed at January 5, 2015. The loan accrues interest at 12% per annum, interest compounds quarterly, and interest and principal is due at the maturity. The loan and its related interest was converted to 614,344 shares of common stock on August 8, 2013.

Interest expense for the three months ended March 31, 2013 was \$24,419. Accrued interest payable related to the note payable were \$306,313 at March 31, 2013. Milestone had also secured a line of credit, from this shareholder, for \$1.3 million which was converted into equity in 2009. However, the accrued interest remaining on the line of credit was not converted and the remaining balance at March 31, 2013 was \$74,669 and accrued interest at 6%, per annum.

Additionally, Milestone has an agreement with the manufacturer of the *CompuDent* and *STA* instruments to accrue interest on their outstanding accounts payable balance. For the quarter ending March 31, 2013, the interest expense for this indebtedness was \$9,445.

## **NOTE – 10 INCOME TAXES**

Milestone's expected federal and state income tax liability and benefit computed at the statutory rate (40%) on the pre-tax income for the quarters ending March 31, 2014 and 2013, amounted to a liability of \$151,000 and \$42,000, respectively. Such expense was recognized in the accompanying financial statements as of March 31, 2014 with recognition of a net operating loss carryforward. Due to Milestone's history of past operating losses, which required a full valuation

allowances for all of Milestone's deferred tax assets at March 31, 2014 and 2013, no recognition was given to the utilization of the remaining net operating loss carryforwards.

**NOTE – 11 STOCK ISSUANCES**

During the three months ended March 31, 2014, Milestone issued 6,986 shares of common stock valued at \$11,875 for payment of employee compensation. In addition, 95,000 shares are to be issued on the exercised of certain stock options at a price of \$0.40 per share during the quarter ending March 31, 2014. Milestone issued 13,939 shares of common stock valued at \$22,500 for payment of consulting services. In the first quarter of 2014, Milestone's to be issued shares for the Board are 30,000 valued at \$55,200 for their Directors' compensation.

**NOTE – 12 RELATED PARTY**

A shareholder of Milestone is also a shareholder of a major supplier of handpieces to Milestone. In addition, he is an investor in the PRC entity, Beijing 3H, which entered into a Medical Joint Venture agreement with Milestone. Milestone purchased \$824,574 and \$663,420 from the supplier for the three months ended March 31, 2014 and 2013, respectively. Milestone owed \$671,777 and \$1,024,653 to this supplier as of March 31, 2014 and December 31, 2013, respectively.

In the first quarter of 2013, the CEO of Milestone loaned the Milestone \$50,000 for use in capitalizing a fifty percent equity portion in the joint venture with Milestone Education LLC. There is no interest to this agreement and the loan was paid in April 2014.

**NOTE – 13 SIGNIFICANT CUSTOMERS**

Milestone had three customers (distributors) for the three months ended March 31, 2014, that had approximately 57% of its net product sales and three customers (distributors) that had approximately 49% of its net product sales for three months ended March 31, 2013. Milestone had accounts receivable for one major customer that amounted to \$621,062 representing 51% of gross accounts receivable as of March 31, 2014 and accounts receivable for one major customer that amounted to \$732,762, or 48% of gross accounts receivable as of December 31, 2013, respectively.

Milestone's sales by product and by geographical region are as follows:

	<u>Three Months Ended March 31,</u>	
	<u>2014</u>	<u>2013</u>
Instruments	\$ 840,981	\$ 517,450
Handpieces	1,733,217	1,925,663
Other	46,636	46,429
	<u>\$ 2,620,834</u>	<u>\$ 2,489,542</u>
United States	\$ 1,213,643	\$ 1,300,500
Canada	24,736	55,602
Other Foreign	1,382,455	1,133,440
	<u>\$ 2,620,834</u>	<u>\$ 2,489,542</u>

**NOTE – 14 PENSION PLANS**

Milestone has a defined contribution plan that allows eligible employees to contribute part of their salary through payroll deductions. Milestone does not contribute to this plan but does pay the administrative costs of the plan, which are not significant.

In March 2014, the Board of Directors approved the Compensation Committee's request to amend the Chief Executive Officer of Milestone's employment agreement to provide benefits to make payments of \$203,111 per year for five years to the Executive, or as he directs such payments to a third party, to fund his acquisition of, or contribution to an annuity, pension, or deferred distribution plan or for an investment for the Executive and his family. For the quarter ended March 31, 2014, approximately \$17,000 was charged to expenses for this commitment.

## **NOTE – 15 COMMITMENTS AND OTHER**

### *Contract Manufacturing Arrangement*

Milestone has informal arrangements for the manufacture of its products. *STA*, single tooth anesthesia, *CompuDent* and *CompuMed* instruments are manufactured for Milestone by Tricor Systems, Inc. pursuant to specific purchase orders. The *STA* and *The Wand Handpiece with Needle* is supplied to Milestone by a contractor in the United States, which arranges for its manufacture with two factories in China.

The termination of the manufacturing relationship with any of the above manufacturers could have a material adverse effect on Milestone's ability to produce and sell its products. Although alternate sources of supply exist and new manufacturing relationships could be established, Milestone would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, whether or not as a result of termination of such a relationship, would adversely affect Milestone.

The technology underlying the *SafetyWand* and *CompuFlo*, and an improvement to the controls for *CompuDent* were developed by the Director of Clinical Affairs and assigned to us. Milestone purchased this technology pursuant to an agreement dated January 1, 2005. The Director will receive additional payments of 2.5% of the total sales of products using certain of these technologies, and 5% of the total sales of products using certain other of the technologies. In addition, the Director is granted, pursuant to the agreement, an option to purchase, at fair market value on the date of the grant, 8,333 shares of the common stock upon the issuance of each additional patent relating to these technologies. If products produced by third parties use any of these technologies (under license from us) then the Director will receive the corresponding percentage of the consideration received by Milestone for such sale or license. Milestone expensed the Director's royalty fees of \$104,197 and \$93,186 for the three months ended March 31, 2014 and 2013, respectively. Additionally, Milestone expensed consulting fees to the Director of \$14,300 and \$39,000 for the three months ended March 31, 2014 and 2013, respectively.

In January 2010, Milestone issued a purchase order to Tricor Systems Inc for the purchase of 12,000 *STA Instruments* to be delivered over the next three years. The purchase order is for \$5,261,640. As of March 31, 2014, Milestone's production and sales of instruments to this commitment has been delayed. Consequently, advances on contracts have been classified as current and long term at March 31, 2014.

In August 2013, a shareholder of Milestone entered a three year agreement with Milestone to provide financial and business strategic services. The fee for these services are \$100,000 annually.

### *Subsequent Event*

In April 2014, the officers of Milestone elected to receive a total of approximately 980,000 shares of previously recorded shares to be issued. As a result, the 980,000 shares have been subsequent to March 31, 2014 will be recorded as issued and outstanding shares at March 31, 2014.

In May 2014, the State Food and Drug Administration of the PRC (SFDA) granted registration approval for the sale of the *STA* handpieces in China.

## **ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.**

The following discussions of our financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this Form 10-Q. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements.

### **OVERVIEW**

In 2014, Milestone remains focused on advancing efforts to achieve our two primary objectives; those being:

- Enhancing our global reach by partnering with distribution companies in the medical sector and
- Optimizing our tactical approach to product sales and marketing in order to materially increase penetration of the global dental and medical markets with our proprietary, patented Computer-Controlled Local Anesthesia Delivery (C-CLAD) solution, the *STA Single Tooth Anesthesia Instrument (STA Instrument)*

#### ***STA Instrument Growth***

Since its market introduction in early 2007, the *STA Instrument* and a prior computerized controlled local anesthesia delivery product have been used to deliver over 49 million safe, effective and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the *STA Instrument* is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide.

#### ***Global Distribution Network***

##### **United States and Canadian Market**

In November 2012, Milestone entered an exclusive distribution and marketing agreement with a well known U.S. domestic manufacturer and distributor, for the sale and distribution of the *STA instruments* and handpieces in United States and Canada.

Milestone has hired a Domestic Sales Director to refocus our attention on the USA and Canadian markets. The mission of the Domestic Sales Director is to grow our business through marketing our *STA Instrument* to Dental Group Practices, as well as individual dental practitioners.

##### **International Market**

On the global front, we also have granted exclusive marketing and distribution rights for the *STA Instrument* to select dental suppliers in various international regions in Asia, Africa, South America and Europe. They include Istrodent in South Africa and Unident in the Scandinavian countries of Denmark, Sweden, Norway and Iceland.

In early October 2012, the State Food and Drug Administration (SFDA) of the People’s Republic of China approved Milestone’s *Single Tooth Anesthesia System® (STA System)*. In May 2014, the SFDA granted registration approval for the sale of *STA* hand pieces in China.

Shortly before the end of the second quarter 2009, we announced that we were refining our international marketing strategy to gain greater access to and penetration of the international dental markets for the *STA Instrument*, *CompuDent* and related disposable handpieces. The new sales strategy provides for increasing hands-on oversight and support of our existing international distribution network, while also attracting new distributors throughout Europe, Asia and South America. To assist in this endeavor, Milestone added in the spring of 2010 an International Sales Director to focus on the growth of our products outside the USA and Canada.

In July 2011, we entered into a definitive joint venture agreement with Beijing 3H (Heart-Help-Health) Scientific Technology Co., Ltd. (Beijing 3H) for the development, commercialization, manufacture and marketing of epidural and intra-articular injection medical instruments. Milestone Scientific holds a 45.5% interest in the joint venture and shareholders of Beijing 3H and others hold a 45.5% interest (the “Medical Joint Venture”). The Beijing 3H shareholders include a large shareholder in Milestone who is also the principal of a supplier to Milestone.

### **Segmented Sales Performance**

The following table shows a breakdown of Milestone’s product sales (net), domestically and internationally, by product category, and the percentage of product sales (net) by each product category:

	<u>Three Months Ended March 31,</u>			
	<u>2014</u>		<u>2013</u>	
<b>DOMESTIC</b>				
Instruments	\$ 158,708	13.1%	\$ 208,139	16.0%
Handpieces	1,025,493	84.5%	1,056,051	81.2%
Other	29,442	2.4%	36,310	2.8%
Total Domestic	<u>\$ 1,213,643</u>	<u>100.0%</u>	<u>\$ 1,300,500</u>	<u>100.0%</u>
<b>INTERNATIONAL</b>				
Instruments	\$ 682,273	48.5%	\$ 309,311	26.0%
Handpieces	707,724	50.3%	869,612	73.1%
Other	17,194	1.2%	10,119	0.9%
Total International	<u>\$ 1,407,191</u>	<u>100.0%</u>	<u>\$ 1,189,042</u>	<u>100.0%</u>
<b>DOMESTIC/INTERNATIONAL ANALYSIS</b>				
Domestic	\$ 1,213,643	46.3%	\$ 1,300,500	52.2%
International	1,407,191	53.7%	1,189,042	47.8%
Total Product Sales	<u>\$ 2,620,834</u>	<u>100.0%</u>	<u>\$ 2,489,542</u>	<u>100.0%</u>

We earned gross profits of 66% and 67% for the three months ended March 31, 2014 and 2013, respectively. However, the revenues and related gross profits have not been sufficient to support overhead, new product introduction and research and development expenses. Although we anticipate expending funds for research and development in 2014, these amounts will vary based on the operating results for each quarter. We incurred operating losses and negative cash flows from operating activities every year since our inception, except for 2013. At March 31, 2014, we believe that we do not have sufficient cash reserves to meet all of our anticipated obligations for the next twelve months. We are actively pursuing the generation of positive cash flows from operating activities through increase in revenue, assessment of current contracts and current negotiations. There is no assurance that we will be able to achieve positive operating cash flows or that additional capital can be raised on terms and conditions satisfactory to us, if at all. If additional capital is required and it cannot be raised, then we would be forced to curtail our development activities, reduce marketing for existing dental products or adopt other cost saving measures, any of which might negatively affect our operating results.

### **Summary of Significant Accounting Policies, Judgments and Estimates**

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to accounts receivable, inventories, stock-based compensation, and contingencies. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the

carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions or conditions.

#### *Accounts Receivable*

The realization of accounts receivable current and long-term will have a significant impact on us. Consequently, Milestone estimates its allowance for doubtful accounts resulting from the inability of its customers to make payments for amounts billed. The collectability of outstanding amounts is continually assessed.

#### *Inventories*

Inventory costing, obsolescence and physical control are significantly important to the on-going operation of the business. Inventories principally consist of finished goods and component parts stated at the lower of cost (first-in, first-out method) or market. Inventory quantities on hand are reviewed on a quarterly basis and a provision for excess and obsolete inventory is recorded if required based on past and expected future sales.

#### *Investment in Medical Joint Venture*

We entered into a Medical Joint Venture with a third party, Beijing 3H, for the development and commercialization of two medical products. We own 45.5% percent of the Medical Joint Venture and have recorded our investment on the equity basis of accounting. Milestone's proportionate share of expenses incurred by the Medical Joint Venture will be charged to the Statement of Operations on a periodic basis.

#### *Impairment of Long-Lived Assets*

Our long lived assets consisting principally of patents and trademarks are the foundation of our business. We review long-lived assets for impairment whenever circumstances and situations change such that there is an indication that the carrying amounts may not be recoverable. The carrying value of the asset is evaluated in relation to the operating performance and future undiscounted cash flows of the underlying assets.

#### *Revenue Recognition*

Revenue from product sales is recognized net of discounts and allowances to the domestic distributors on the date of shipment for essentially all shipments, since the shipment terms are FOB warehouse. We will recognize revenue on date of arrival of the goods at the customer's location where shipments are FOB destination. Shipments to international distributors are FOB the warehouse and revenue is therefore recognized on shipment. In both cases the price to the buyer is fixed and the collectability is reasonably assured. Further, we have no obligation on these sales for any post installation, set-up or maintenance, these being the responsibility of the buyer. Customer acceptance is considered made at delivery. Milestone's only obligation after sale is the normal commercial warranty against manufacturing defects if the alleged defective unit is returned within the warranty periods, which volumes have historically been immaterial.

### **Results of Operations**

The consolidated results of operations for the three months ended March 31, 2014 compared to the same three month period in 2013 reflect our focus and development on the *Wand/STA Instrument*, as well as continuing efforts on identifying collaborative partners which will allow for new product development utilizing our *CompuFlo* technology.

The following table sets forth, for the periods presented, the statement of operations data as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results.

	Three Months Ended March 31			
	2014		2013	
Net sales	\$2,620,834	100%	\$2,489,542	100%
Cost of products sold	882,997	34%	812,043	33%
Gross Profit	1,737,837	66%	1,677,499	67%
Selling, general and administrative expenses	1,392,869	53%	1,387,901	53%
Research and development expenses	15,720	1%	121,837	5%
Operating expenses	1,408,589	54%	1,509,738	58%
Income from operations	329,248	13%	167,761	6%
Total other expenses	(134,414)	-5%	(17,015)	-1%
Net income	\$ 194,834	7%	\$ 150,746	6%

***Three months ended March 31, 2014 compared to three months ended March 31, 2013***

Total product sales for the three months ended March 31, 2014 and 2013 were \$2,620,834 and \$2,489,542, respectively. The total increase in product sales of \$131,292 or 5%, in 2014 from 2013 is principally the result of increase in international revenues. Domestic instruments sales decreased by \$49,430 in 2014 from 2013. In the domestic market, although the total handpiece sales decreased by \$30,558 or 3% in 2014 over 2013, *STA* handpiece sales increased by \$23,902 in 2014 over 2013. The training component of our business is showing positive results on the increased *STA* handpiece sales in the domestic market. On the international front, instruments sales increased in the first quarter of 2014 from 2013 by 372,961 or 121%, principally due to a significant increase in the sales of the *STA Instruments* by \$383,086 in 2014 over 2013 due to a change in marketing strategy for our international business. Internationally, handpiece sales decreased by \$161,887 or 19% due to a decrease in *Wand* handpieces sales of \$365,450 in 2014 over 2013. *STA* handpiece sales increased by \$203,563 or 67% for the first quarter 2014 over 2013. The sales of *Wand Plus Instruments* to the European community ceased in 2012 due to a change in the regulations. The *Wand Plus* users in Europe will continue to own, utilize and purchase the handpieces.

Cost of products sold for the three months ended March 31, 2014 and 2013 were \$882,997 and \$812,043, respectively, an increase of \$70,954 or 9%.

For the three months ended March 31, 2014, Milestone generated a gross profit of \$1,737,837 or 66%, as compared to a gross profit of \$1,677,499, or 67%, for the three months ended March 31, 2013. The total increase in gross profit dollars of \$60,338 is primarily due to an increase in revenue.

Selling, general and administrative expenses for the three months ended March 31, 2014 and 2013 were \$1,392,869 and \$1,387,901, respectively. This increase in expenses of \$4,968 is described in the following sections of this report. Milestone continues to focus on controlling expenses in all categories. The first quarter of 2014 noted several areas of savings as Milestone continues on its planned business model change, through the training and education hygienist program. First, marketing expenses decreased by approximately \$19,000 as Milestone targeted this venue as a more costly method to present our *Wand/STA Instrument*. Milestone has decided to focus its attention on the national shows that are focused on a higher attendance by individual dentists as well as dental practice groups. Additionally, a large portion of our previous marketing and selling costs in the U. S. and Canada are now incurred by our exclusive *STA* distributor. Sales expenses also decreased by approximately \$12,000 during the first quarter of 2014 principally in travel related cost. Other expenses for the quarter increased by approximately \$153,000 as compared to the same period in 2013. The reserve for bad debt increase by approximately \$56,000 as Milestone reversed a portion of the bad debt reserve based on payments made by a Chinese distributor in the first quarter of 2013 and the reserves were completely reversed in 2013. Consulting expenses increased by approximately \$60,000. There was an increase in royalty commission by approximately \$11,000 as compared to the same period in 2013. International travel cost increased by approximately \$4,000. The offset for other expenses are the decreases in excise tax of approximately \$20,000 due to the new law passed in 2013. Salaries decreased

by approximately \$99,000 in this quarter over the comparable quarter in the prior year. Legal fees decreased by approximately \$17,000 in the aggregate for routine litigation and patent annuities.

Research and development expenses for the three months ended March 31, 2014 and 2013 were \$15,720 and \$121,837, respectively, a decrease of \$106,117 or 87%, due to the software enhancement of the *STA Instrument* in 2013.

The income from operations for the three months ended March 31, 2014 and 2013 was \$329,248 and \$167,761, respectively. The \$161,487, or 96%, increase is explained above.

Interest expense of \$34,558, relating to the \$1.3 million line of credit which was subsequently converted into common stock in December 2009 and the \$450,000 long term note payable, was charged for the three months ended March 31, 2013, this was converted to common stock on August 8, 2013. Additionally, Milestone accrued interest expense of \$9,445 and \$20,901 for the overdue accounts payable on the balance to the instrument assembler at March 31, 2013 and this did not happen in 2014.

There is a Loss on the Medical Joint Venture of \$130,523 for the quarter ending March 31, 2014. There was a Loss on the Education Joint Venture of \$3,415 for the quarter ending March 31, 2014.

For the reasons explained above, net income for the three months ended March 31, 2014 and 2013 was \$194,834 and \$150,746, respectively. The \$44,088, or 29%, increase in net income is primarily a result of an increase in gross margin dollars of \$60,338 enhanced by an increase in selling, general and administrative expenses of \$4,968 and an increase of \$133,939 for the non-cash loss on the joint ventures offset by a decrease in research and development expense of \$106,117.

## **Liquidity and Capital Resources**

As of March 31, 2014, Milestone had cash and cash equivalents of \$1,398,847 and a positive working capital of \$4,162,674. Milestone had net income of \$194,834 and \$150,746 for the three months ended March 31, 2014 and 2013, respectively. The positive working capital of \$4,162,674 in 2014 was the result of classification of the advances on contracts from noncurrent to current because of the 5,633 *STA* instruments Milestone will receive in 2014. Additionally, the accounts payable due this supplier is \$76,102 as of March 31, 2014. This represents a \$38,742 increase over December 31, 2013.

There was a substantial increase in working capital at March 31, 2014, of \$1,818,540 from \$2,344,135 at December 31, 2013. The net current asset increased by \$1,491,531. The significant current asset changes are: current accounts receivable decreased by \$311,481, cash increased by \$251,649 and inventory increased by \$423,294. Current liabilities decreased by \$327,008.

Milestone, at March 31, 2014, has agreed to accept the remaining 5,633 *STA* instruments by November 30, 2014, thereby decreasing the noncurrent advances on contracts of \$1,361,999. Milestone continues to take positive steps to maintain adequate inventory levels and advances on contracts to maintain available inventory to meet our domestic and international sales requirements. Cash flows from operating activities for the three months ended March 31, 2014 and 2013 were a positive \$276,968 and a negative \$83,667, respectively.

For the three months ended March 31, 2014, our net cash provided by operating activities was \$276,968. This was attributable primarily to a net income of \$194,834 adjusted for noncash items of \$245,625, principally common stock issued for compensation, consulting and vendor services, and changes in operating assets and liabilities of \$163,491.

Milestone has incurred operating losses and negative cash flows from operating activities since its inception, except for the four quarters of 2013. Milestone is actively pursuing the generation of positive cash flows from operating activities through increases in revenues based upon management's assessment of present contracts and current negotiations and reductions in operating expenses. As of March 31, 2014, Milestone believes that it does not have sufficient cash reserves to meet all of its anticipated obligations for the next twelve months. However, if Milestone requires a higher level of marketing and sales effort, or if Milestone is unable to continue generating positive cash flows

from its operating activities it will need to raise additional capital. There is no assurance that Milestone will be able to continue to achieve positive operating cash flows or that additional capital can be raised on the terms and conditions satisfactory to Milestone if at all. If additional capital is required and it cannot be raised, then Milestone would be forced to curtail its development activities, reduce marketing expenses for existing dental products or adopt other cost savings measures, any of which might negatively affect Milestone's operating results.

Milestone's historical losses and negative operating cash flows raises substantial doubt about its ability to continue as a going concern. The accompanying financial statements do not include any adjustment that might result from the outcome of this uncertainty.

### **Item 3. Quantitative and Qualitative Disclosures about Market Risk**

As a smaller reporting company, we are not required to provide the information required by this Item.

### **Item 4. Controls and Procedures**

Milestone's management, including the Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the design and operation of Milestone's disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report (the "Evaluation Date"). Based upon that evaluation, Milestone's Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of the Evaluation Date are effective to ensure that information required to be disclosed in the reports Milestone files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to Milestone's management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding disclosure.

There were no changes in Milestone's internal control over financial reporting identified in connection with the evaluation that occurred during Milestone's last fiscal quarter ended March 31, 2014 that have materially affected, or that are reasonably likely to materially affect, Milestone's internal controls over financial reporting.

## **PART II – OTHER INFORMATION**

### **ITEM 1. LEGAL PROCEEDINGS**

None.

### **ITEM 1A. RISK FACTORS**

As a smaller reporting company, we are not required to provide the information required by this Item.

### **ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

#### Recent Sales of Unregistered Securities

In the quarter ended March 31, 2014, Milestone issued total 20,925 shares valued at \$34,375 as follows:

	<u>Shares</u>	<u>\$</u>
Shares issued for services	13,939	\$ 22,500
Shares issued for Employee Compensation	<u>6,986</u>	<u>11,875</u>
	20,925	\$ 34,375

These issuances were exempt from registration pursuant to Section 4 (a)(2) of the Securities Act of 1933, as amended (the “Act”) and a legend restricting the sale, transfer, or other disposition of these shares other than in compliance with the Act was imprinted on stock certificates evidencing the shares.

### **ITEM 3. DEFAULT UPON SENIOR SECURITIES**

None.

### **ITEM 4. MINE SAFETY DISCLOSURES**

Not applicable.

### **ITEM 5. OTHER INFORMATION**

None.

### **ITEM 6. EXHIBITS**

The following exhibits are filed herewith:

- 10.22 Amendment to the Employment Agreement with Leonard Osser, effective March 17, 2014.\*
- 31.1 Chief Executive Officer Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.\*
- 31.2 Chief Operating Officer Certification pursuant to section 302 of the Sarbanes-Oxley Act of 2002.\*
- 32.1 Chief Executive Officer Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.\*
- 32.2 Chief Operating Officer Certification pursuant to section 906 of the Sarbanes-Oxley Act of 2002.\*

101.INS	XBRL Instance Document.*
101.SCH	XBRL Taxonomy Extension Schema Document.*
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.*
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.*
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.*
<u>101.DEF</u>	XBRL Taxonomy Extension Definition Linkbase Document.*

\* Filed herewith.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

### **MILESTONE SCIENTIFIC INC.**

/s/ Leonard Osser

Leonard Osser  
Chief Executive Officer  
(Principal Executive Officer)

/s/ Joseph D'Agostino

Joseph D'Agostino  
Chief Operating Officer  
Chief Financial Officer  
(Principal Financial Officer)

Date: May 13, 2014

**Amendment No. 2 to the 2009 Employment Agreement**

Amendment No. 2 to the Employment Agreement dated as of September 1, 2009 (the “2009 Employment Agreement”) between Leonard Osser (the “Executive”) and Milestone Scientific Inc. (the “Company”) as follows:

1. “Section 6. Other Benefits” of the 2009 Employment Agreement is hereby amended to add the following new paragraph (f);

(f) The Company will make payments of \$203,111 per year for five years to the Executive, or as he directs such payments to a third party, to fund his acquisition of, or contribution to, an annuity, pension, or deferred distribution plan or for an investment for the Executive and his family. During the 5-year period commencing in 2014 during which these payments are being made by the Company, the options, if any, payable to the Executive under paragraph 4(c) above shall equal the number of Bonus Shares included in the allotment of Bonus Shares for that year (rather than being in an amount equal to two times the number of Bonus Shares).

2. This Amendment No. 2 supersedes and replaces Amendment No. 1 to the 2009 Employment Agreement.

3. Except as provided for herein, all other provisions of the 2009 Employment Agreement shall remain in full force and effect.

MILESTONE SCIENTIFIC INC.

By: /s/ Joseph D’Agostino  
Joseph D’Agostino,  
Chief Operating and Chief Financial Officer

/s/ Leonard Osser  
Leonard Osser

**Rule 13a-14(a)/15d-14(a) Certification**

I, Leonard Osser, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Milestone Scientific Inc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to Milestone is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, Milestone's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and, I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the Audit Committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 13, 2014

/s/ Leonard Osser  
Leonard Osser  
Chief Executive Officer  
(Principal Executive Officer)

## Exhibit 31.2

### Rule 13a-14(a)/15d-14(a) Certification

I, Joseph D'Agostino, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Milestone Scientific Inc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to Milestone is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and
  - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, Milestone's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and, I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the Audit Committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 13, 2014

/s/ Joseph D'Agostino  
Joseph D'Agostino  
Chief Operating Officer  
Chief Financial Officer  
(Principal Financial Officer)

**Exhibit 32.1**

CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Milestone Scientific Inc on Form 10-Q for the period ending March 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Leonard Osser, Chief Executive Officer of Milestone, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone

Date: May 13, 2014

/s/ Leonard Osser

Leonard Osser  
Chief Executive Officer  
(Principal Executive Officer)

A signed original of this certification has been provided to Milestone and will be retained by Milestone and furnished to the Securities and Exchange Commission or its staff upon request.

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report of Milestone Scientific Inc on Form 10-Q for the period ending March 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Joseph D'Agostino, Chief Financial Officer of Milestone, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of Milestone

Date: May 13, 2014

/s/ Joseph D'Agostino

Joseph D'Agostino  
Chief Operating Officer  
Chief Financial Officer  
(Principal Financial Officer)

A signed original of this certification has been provided to Milestone and will be retained by Milestone and furnished to the Securities and Exchange Commission or its staff upon request.